These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 34339089)
61. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. Keith MP; Gilliland WR Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966 [TBL] [Abstract][Full Text] [Related]
62. Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. Mikuls TR; Cheetham TC; Levy GD; Rashid N; Kerimian A; Low KJ; Coburn BW; Redden DT; Saag KG; Foster PJ; Chen L; Curtis JR Am J Med; 2019 Mar; 132(3):354-361. PubMed ID: 30503879 [TBL] [Abstract][Full Text] [Related]
63. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Jutkowitz E; Choi HK; Pizzi LT; Kuntz KM Ann Intern Med; 2014 Nov; 161(9):617-26. PubMed ID: 25364883 [TBL] [Abstract][Full Text] [Related]
64. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450 [TBL] [Abstract][Full Text] [Related]
65. Prevention of colchicine toxicity in patients with gout. Dalbeth N; Gow P N Z Med J; 2007 Apr; 120(1252):U2503. PubMed ID: 17460750 [No Abstract] [Full Text] [Related]
66. Allopurinol initiation and all-cause mortality in the general population. Dubreuil M; Zhu Y; Zhang Y; Seeger JD; Lu N; Rho YH; Choi HK Ann Rheum Dis; 2015 Jul; 74(7):1368-72. PubMed ID: 24665118 [TBL] [Abstract][Full Text] [Related]
67. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Becker MA; MacDonald PA; Hunt BJ; Jackson RL Diabetes Obes Metab; 2013 Nov; 15(11):1049-55. PubMed ID: 23683134 [TBL] [Abstract][Full Text] [Related]
68. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Stamp LK; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Chapman PT Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998 [TBL] [Abstract][Full Text] [Related]
69. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724 [TBL] [Abstract][Full Text] [Related]
71. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. Smolen LJ; Gahn JC; Mitri G; Shiozawa A Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247 [TBL] [Abstract][Full Text] [Related]
72. Rogue one: a story of tophaceous gout in the spine. Dwarki K; Dothard A; Abadie B; Miles MC BMJ Case Rep; 2018 Apr; 2018():. PubMed ID: 29666075 [TBL] [Abstract][Full Text] [Related]
73. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314 [TBL] [Abstract][Full Text] [Related]
74. Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database. Kim JW; Kwak SG; Park SH Korean J Intern Med; 2018 Jan; 33(1):228-229. PubMed ID: 28823114 [No Abstract] [Full Text] [Related]
75. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941 [TBL] [Abstract][Full Text] [Related]
76. Mortality in Patients With Gout Treated With Allopurinol: A Systematic Review and Meta-Analysis. Hay CA; Prior JA; Belcher J; Mallen CD; Roddy E Arthritis Care Res (Hoboken); 2021 Jul; 73(7):1049-1054. PubMed ID: 32286732 [TBL] [Abstract][Full Text] [Related]
77. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Zhang T; Pope JE Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501 [TBL] [Abstract][Full Text] [Related]
79. Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. Coleshill MJ; Day RO; Tam K; Kouhkamari M; Caillet V; Aung E; Kannangara DRW; Cronin P; Rodgers A; Stocker SL Br J Clin Pharmacol; 2022 Nov; 88(11):4894-4901. PubMed ID: 35675118 [TBL] [Abstract][Full Text] [Related]
80. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data. Singh JA; Cleveland JD Eur Heart J; 2019 Sep; 40(36):3046-3054. PubMed ID: 30919894 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]